title: [Efficacy and safety of Adalimumab in Crohn's disease].
abstract: BACKGROUND
  Adalimumab is the first subcutaneously self administered fully human anti-TNFa.
  
  
  OBJECTIVE
  To determine efficacy and safety of Adalimumab therapy in Crohn disease.
  
  
  METHODS
  Literature review.
  
  
  RESULTS
  Adalimumab has been evaluated for its effect in inducing and maintaining remission and its steroid-sparing effect of refractory Crohn's disease. In addition, it offers a significant treatment option in patients who have lost response to or become intolerant to Infliximab. Results also suggest efficacy of Adalimumab in fistulising Crohn's disease but more studies are needed. Adalimumab was well tolerated and studies show that all anti-TNF inhibitors have similar safety profiles.
authors.affiliation: Service de Gastro-enterologie, A. Hopital la Rabta, Tunis.
authors.forename: M
authors.initials: M
authors.lastname: Serghini
authors.forename: W
authors.initials: W
authors.lastname: Haddad
authors.forename: H
authors.initials: H
authors.lastname: Jeddi
authors.forename: S
authors.initials: S
authors.lastname: Karoui
authors.forename: N
authors.initials: N
authors.lastname: Ben Mustapha
authors.forename: L
authors.initials: L
authors.lastname: Kallel
authors.forename: M
authors.initials: M
authors.lastname: Fekih
authors.forename: S
authors.initials: S
authors.lastname: Matri
authors.forename: J
authors.initials: J
authors.lastname: Boubaker
authors.forename: A
authors.initials: A
authors.lastname: Filali
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab